Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | PLD1 | Q13393 | 7/20 | 0.60 |
| ▸ | PLD2 | O14939 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138300 | 0.83 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| SCHEMBL9963429 | 0.80 | SLC6A9 (0.68) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| SCHEMBL8219272 | 0.79 | PLD1 (0.81) | SLC6A9OPRM1SLC6A5PLD1PLD2 | |
| SCHEMBL5556903 | 0.78 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| SCHEMBL5561878 | 0.78 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| SCHEMBL1138347 | 0.78 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| Trifluoroacetic Acid SCHEMBL11972709 | 0.78 | PLD1 (0.63) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| SCHEMBL11991351 | 0.78 | PLD1 (0.67) | SLC6A9OPRM1SLC6A5KCNH2PLD1 | |
| SCHEMBL1140021 | 0.77 | SLC6A9 (0.78) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL8223175 | 0.77 | PLD1 (0.82) | SLC6A9PLD1PLD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| EP-2456307-B1 | ISOFORM SELECTIVE PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9127005-B2 | Isoform selective phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120214832-A1 | ISOFORM SELECTIVE PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY | 2012-08-23 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214832-A1 | ISOFORM SELECTIVE PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PLA2G2D | SLC6A9 3344/4885OPRM1 3250/4885SLC6A5 3525/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | SLC6A9 3090/4885OPRM1 3240/4885SLC6A5 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.